On September 8, 2022 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), reported that the Company will hold a conference call on Thursday, September 15, 2022, to give an update on business progress during the first half of 2022 (Press release, Innate Pharma, SEP 8, 2022, View Source [SID1234619277]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Speakers during the call will be:

Mondher Mahjoubi, Chief Executive Officer
Joyson Karakunnel, Executive Vice President, Chief Medical Officer
Frédéric Lombard, Senior Vice President, Chief Financial Officer
Yannis Morel, Executive Vice President, Product Portfolio Strategy & Business Development
Details for the Virtual Event

Participants may also join via telephone to ask questions by registering in advance of the event at: View Source Upon registration, participants will be provided with dial-in numbers, a direct event passcode and a unique registrant ID that they may use 10 minutes prior to the event start to access the call. Call reminders will also be sent to registered participants via e-mail the day prior to the event.

This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com. A replay of the webcast will be available on the Company website for 90 days following the event.

On September 8, 2022 Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress" or "the Company"), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, reported that Lindsay A. Rosenwald, M.D., Chairman and Chief Executive Officer, will present a corporate update virtually at the H.C. Wainwright 24th Annual Global Investment Conference and the Company will participate in one-on-one meetings on Tuesday, September 13, 2022 (Press release, Fortress Biotech, SEP 8, 2022, View Source [SID1234619276]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 8, 2022 Cardiff Oncology, Inc. ( Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, reported that company management will present and participate in 1×1 investor meetings at the Baird Global Healthcare Conference and the H.C. Wainwright 24th Annual Global Investment Conference taking place in New York, NY, on September 13 – 14, 2022, and September 12 – 14, 2022, respectively (Press release, Cardiff Oncology, SEP 8, 2022, View Source [SID1234619275]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on the presentations can be found below.

Baird Global Healthcare Conference

H.C. Wainwright 24th Annual Global Investment Conference

A replay of the H.C. Wainwright presentation will be available by visiting the "Events" section of the Cardiff Oncology website after its conclusion.

On September 8, 2022 Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, reported that James Oliviero, President and Chief Executive Officer, will participate in two upcoming investor conferences. Details are as follows (Press release, Fortress Biotech, SEP 8, 2022, View Source [SID1234619274]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 24th Annual Global Investment Conference:

Mr. Oliviero will be presenting a corporate update at the H.C. Wainwright 24th Annual Global Investment Conference. A webcast of the company’s presentation will be available on the News & Events page, located within the Investors section of Checkpoint’s website, View Source, for approximately 30 days after the meeting. Checkpoint will also participate in one-on-one meetings during the conference.

Lake Street’s 6th Annual Best Ideas Growth Conference

On September 8, 2022 Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, reported that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in New York City (Press release, Mustang Bio, SEP 8, 2022, View Source [SID1234619273]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the events are as follows:

H.C. Wainwright 24th Annual Global Investment Conference: The company will present a corporate update on Monday, September 12, 2022, at 9:30 a.m. ET and will participate in one-on-one meetings during the conference. A webcast of the company’s presentation will be available on the News & Events page of the Investor Relations section of Mustang’s website, www.mustangbio.com, for approximately 30 days after the meeting.
Cantor Cell & Gene Therapy Conference: The company will participate in a panel presentation on Thursday, September 15, 2022, at 10:40 a.m. ET, titled, "You Can’t Get Anywhere without the CAR-T Keys or GMP Van: Why Manufacturing is Essential." The company will also participate in one-on-one meetings during the conference.